Adicet Bio (NASDAQ:ACET) & Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Survey

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Adicet Bio (NASDAQ:ACET) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for Lakefront Biotherapeutics American Depositary Shares and Adicet Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1	6	0	1	2.12
Adicet Bio	1	1	5	1	2.75

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $36.50, indicating a potential upside of 19.16%. Adicet Bio has a consensus target price of $48.80, indicating a potential upside of 446.17%. Given Adicet Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Adicet Bio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Adicet Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Adicet Bio	N/A	-80.35%	-65.44%

Institutional and Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and Adicet Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.60	$363.05 million	($1.41)	-21.72
Adicet Bio	N/A	N/A	-$116.80 million	($14.90)	-0.60

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Adicet Bio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Adicet Bio beats Lakefront Biotherapeutics American Depositary Shares on 7 of the 12 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.